WHO decision to halt trials of hydroxychloroquine for COVID-19 is not correct: CSIR DG

Video credit: ANI
Published on May 29, 2020 - Duration: 01:36s

WHO decision to halt trials of hydroxychloroquine for COVID-19 is not correct: CSIR DG

Council of Scientific and Industrial Research (CSIR), Director General Shekhar Mande said that WHO decision to halt trials of hydroxychloroquine for COVID-19 is not correct and it must resume as early as possible.

"The study was published in Lancet on hydroxychloroquine and chloroquine and its effect on COVID-19.

It is an observational study with statical parameters and analysis which is not sufficiently good.

In our letter to the Lancet editor, we have written that the study design and statical interferences are not right therefore study does not deserve any attention of the readers.

We believe that WHO's decision to temporarily halt the trials is not correct and demanded that the clinical trials of hydroxychloroquine for its use in COVID-19 cases must resume as early as possible," said Mande after WHO halts clinical trials of hydroxychloroquine for COVID-19.

Advertisement

You are here

Related videos from verified sources

What does airborne Covid mean? CSIR DG explains as WHO prepares brief 02:21
Video credit: HT Digital Content - Published 6 days ago 

WHO halts malaria drug in COVID-19 trials 01:05
Video credit: Reuters Studio - Published 2 weeks ago 

Return To Sender? Millions Of Hydroxychloroquine Pills Locked In Limbo 00:36
Video credit: Wochit - Published on June 18, 2020 

You might like